Tafoxiparin is protected by several patent families

Dilafor´s drug product candidate tafoxiparin, is protected by several patent families with potential patent expiries in 2043. Substance patent protection for tafoxiparin has been granted worldwide. Further patent applications are also on file, covering additional aspects of Dilafor´s development programme.


“I am delighted that my 45 years’ preclinical and clinical research have reached this significant milestone. There is a great medical need for new treatments to address initiation of labor and I hope that tafoxiparin will make a difference for all these pregnant women.”

Professor Gunvor Ekman Ordeberg, Founder and CMO